Guidance

All influenza vaccines marketed in the UK for the 2024 to 2025 season (text version)

Updated 12 June 2024

Supplier Name of product Vaccine type Age indications Ovalbumin content micrograms per dose Contact details
AstraZeneca UK Ltd Fluenz® Tetra [see note 1] Quadrivalent LAIV (live attenuated influenza vaccine) supplied as nasal spray suspension From 24 months to less than 18 years of age Less than 0.024 micrograms per 0.2 ml dose 0845 139 0000
Sanofi Quadrivalent influenza vaccine QIVe (standard egg-grown quadrivalent influenza vaccine), split virion, inactivated From 6 months Equal to or less than 0.05 micrograms per 0.5 ml dose 0800 854 430
Viatris Influvac® sub-unit Tetra QIVe (standard egg-grown quadrivalent influenza vaccine), surface antigen, inactivated From 6 months Equal to or less than 0.1 micrograms per 0.5 ml dose 0800 358 7468
CSL Seqirus UK Cell-based quadrivalent influenza vaccine Seqirus▼ QIVc (cell-based quadrivalent influenza vaccine), surface antigen, inactivated From 6 months Egg-free 0345 0093 804
Sanofi Quadrivalent Influenza Vaccine (Split Virion, Inactivated) High-Dose ▼ QIV-HD (High-dose egg-grown quadrivalent influenza vaccine), split virion, inactivated 60 micrograms HA/strain From 60 years Equal to or less than 1 microgram per 0.7ml dose 0800 854 430
CSL Seqirus UK Adjuvanted quadrivalent influenza vaccine Seqirus▼ aQIV (adjuvanted egg-grown quadrivalent influenza vaccine) surface antigen, inactivated, adjuvanted with MF59C.1 From 65 years Equal to or less than 1 micrograms per 0.5 ml dose 0345 0093 804

The inverted Black Triangle symbol (▼ ) is used when a drug or vaccine is being monitored under the Black Triangle Scheme.

[note 1] An alternate product formulation may be supplied in the 2024 to 2025 season; potential formulations for 2024 to 2025 season will have the same ovalbumin content threshold of ‘less than 0.024 micrograms per 0.2ml dose.